- Home
- RNA vs MDGL Comparison
RNA vs MDGL Comparison
Compare RNA & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNA | MDGL |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.6M | 12.0B |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RNA | MDGL |
|---|---|---|
| Price | $14.31 | $514.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 12 |
| Target Price | $69.26 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 381.1K | 355.0K |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $88.12 | $58.39 |
| Revenue Next Year | $18.11 | $47.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.95 | $265.00 |
| 52 Week High | $73.06 | $615.00 |
Technical Indicators
Market Signals| Indicator | RNA | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 26.62 | 56.37 |
| Support Level | $13.06 | $503.93 |
| Resistance Level | $72.75 | $610.00 |
| Average True Range (ATR) | 0.56 | 27.19 |
| MACD | 1.73 | 0.19 |
| Stochastic Oscillator | 91.22 | 49.32 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.